Pazopanib for the treatment of renal cell carcinoma and other malignancies. Review uri icon

Overview

abstract

  • Pazopanib (GW-786034) is a second-generation multitargeted tyrosine kinase inhibitor against VEGFR1, -2 and -3, PDGFRalpha, PDGFRbeta and c-Kit. Preclinical evaluation has revealed excellent anti-angiogenic and antitumor activity in several tumors. A phase II clinical trial of pazopanib in untreated or cytokine/bevacizumab-pretreated renal cell carcinoma (RCC) has demonstrated promising activity accompanied by a favorable toxicity profile. A placebo-controlled phase III trial in untreated or cytokine-treated patients with RCC demonstrated a significant improvement in progression-free survival. Ongoing trials are further evaluating pazopanib in a variety of other malignancies.

publication date

  • September 1, 2009

Research

keywords

  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Protein-Tyrosine Kinases
  • Pyrimidines
  • Sulfonamides

Identity

Scopus Document Identifier

  • 75749151307

PubMed ID

  • 19956806

Additional Document Info

volume

  • 45

issue

  • 9